ASML Generated $33B Revenue in 2024 but Sales Declined 3% Year-Over-Year
ASML generated $33B revenue and $8.8B net income in 2024 after shipping 380 new and 38 refurbished lithography systems, but its cyclical equipment sales drove year-over-year revenue swings of +41% in 2023 and -3% in 2024. Analysts forecast 5% sales growth in 2026 while Chinese EUV development threatens market share.
1. Dominant Market Position with Robust 2024 Financials
ASML remains the undisputed leader in semiconductor lithography, responsible for nearly 100% of the extreme ultraviolet (EUV) segment and commanding the majority of the overall lithography market. In 2024, the company reported €33 billion in revenue and €8.8 billion in net income. Its portfolio of tens of thousands of patents underpins high barriers to entry, ensuring that major chipmakers—including its largest customer, Taiwan’s leading foundry—continue to rely on ASML’s multi-hundred-million-dollar EUV systems for their most advanced nodes.
2. Cyclical Order Patterns Undermine Consistent Gains
ASML’s sales are characterized by large, one-off equipment orders that drive significant year-to-year swings. In 2021, revenue jumped 69%, only to dip in 2022; it then rose nearly 41% in 2023 before falling 3% in 2024. Total unit shipments in 2024 reached 380 new systems plus 38 refurbished machines. Analysts project a 31% increase in 2025 revenue versus 2024, but just a 5% gain in 2026. Since 2015, average annualized revenue growth stands at 18%, solid but insufficient for transforming a modest investment into a seven-figure position over a typical investor horizon.
3. Emerging Competition and Patent Challenges
Chinese efforts to reverse-engineer EUV technology threaten to erode ASML’s long-standing intellectual property moat. Beijing aims to field a working domestic EUV prototype by 2028, potentially undermining ASML’s pricing power and future order cadence. While ASML has brought multiple patent infringement suits, enforcement against state-backed competitors may prove limited, particularly if cost-sensitive chipmakers embrace lower-priced alternatives.
4. Valuation Concerns Suggest Patient Entry Points
After a recent 100% rally off its April low, ASML’s valuation metrics appear extended relative to historical averages. Investors who bought during cyclical troughs have generated attractive long-term returns, but the current share premium increases vulnerability to predictable pullbacks when customer capital expenditure slows. A more prudent strategy may be to await a meaningful correction—potentially triggered by softer 2025 orders—before allocating new capital to ASML stock.